TMED9 as a Biomarker for Epithelial Ovarian Cancer (EOC)
November 2022 (Department of Obstetrics and Gynecology, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea)
TMED9 (transmembrane emp24 domain-containing protein 9), which regulates the innate immune system and the protein transport via the ER-Golgi cargo pathway, has been implicated in various cancer types.
Han GH et al., TMED9 Expression Level as a Biomarker of Epithelial Ovarian Cancer Progression and Prognosis. Cancer Genomics Proteomics. 2022 Nov-Dec;19(6):692-702.
A new study from the Yonsei University College of Medicine, Seoul, Republic of Korea, aimed to elucidate the role and clinical significance of TMED9 in EOC (Cancer Genomics & Proteomics 19: 692-702, 2022).
👉 Our rabbit polyclonal antibody anti-TMED9 (HPA014650) was used on 417 tissue samples (212 EOCs, 52 borderline tumors, 83 benign tumors, and 70 non-adjacent normal ovarian epithelia).
The results show:
✅ TMED9 mRNA and protein expression are upregulated in epithelial ovarian cancer compared to the normal ovarian epithelium.
✅ High expression of TMED9 is associated with advanced-stage epithelial ovarian cancer, particularly with the serous cell subtype of ovarian cancer.
✅ TMED9 knockdown reduces migration, invasion, cell proliferation, and colony formation of epithelial ovarian cancer cells.
Overall, the results support the use of TMED9 as a valuable prognostic biomarker and provide evidence for targeting TMED9 as a novel strategy for epithelial ovarian cancer treatment.